MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Ask-gene.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Ask-gene.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Ask-gene.com most likely does not offer any adult content.
Popular pages
-
AskGene Pharma | SmartKine Prodrug Platform | Cytokine Therapeutics
AskGene Pharma is unlocking the full therapeutic potential of cytokine molecules with our innovative SmartKine prodrug platform. Learn more.
-
AskGene IGCC 2023 Oral Presentation: Latest Results of ASKB589 Phase I/II Trial - AskGene
Camarillo, California, June 16, 2023 – AskGene Pharma Inc. today gave an oral presentation at the 15th International Gastric Cancer Congress (IGCC 2023) in Yokohama, Japan of the latest clinical resul...
-
AskGene Achieves “First in Human” Milestone for ASKG915, A First-in-Class Anti-PD-1/IL-15 Prodrug
Camarillo, California, August 21, 2023 – AskGene Pharma Inc. is pleased to announce that the first patient has been dosed at Columbia University Irving Medical Center in New York City in the phase I c...
-
News Archives - AskGene
Camarillo, California, January 26, 2024 – AskGene Pharma Inc. announces dosing of the first patient at a participating site in China for the Phase III pivotal trial of ASKB589. ASKB589 is a CLDN18.2 t...
-
AskGene Presents Latest Results on ASKG315 and ASKG915 at SITC 2022 - AskGene
Camarillo, California, November 15th, 2022 – AskGene presented the pre-clinical results of ASKG315 (IL-15 prodrug) and ASKG915 (PD-1/IL-15 prodrug) at the Society for Immunotherapy of Cancer’s (SITC) ...
-
AskGene Pharma | Cytokine Therapy | Pipeline Overview
AskGene Pharma focuses development efforts on key areas of unmet therapeutic need. See our product pipeline for oncology, autoimmune disease, and ophthalmology.